Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics" but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly period ended October 31, 1998 (Six months ended October 31, 1998 for comparative data).
Status: Development Stage Company in pre-clinical trial stage. No principal operations commenced.
Going Concern: Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated losses and working capital deficit.
Key Financial Metrics
| Metric | Six Months Ended Oct 31, 1998 | Six Months Ended Oct 31, 1997 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(465,623) | $(594,588) |
| Accumulated Deficit | $(10,033,787) | $(9,568,164) |
| Cash and Equivalents (End of Period) | $249,149 | $99,619 |
| Working Capital | $(231,977) | Not explicitly stated (Liabilities exceeded Assets) |
| Total Assets | $488,346 | $985,914 (April 30, 1998) |
| Total Liabilities | $548,116 | $634,361 (April 30, 1998) |
| Net Cash Used in Operating Activities | $(6,817,592) | $(261,431) |
| Net Cash Provided by Financing Activities | $7,678,837 | $330,909 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 22% to $465,623 for the six months ended Oct 31, 1998, compared to $594,588 in the prior year. This was driven by a reduction in General and Administrative (G&A) expenses.
- Expense Composition:
- R&D Expenses: Decreased to $72,855 from $83,533 due to reduced personnel and supplies.
- G&A Expenses: Decreased to $392,723 from $508,659. The prior year included a one-time $180,000 expense for stock issued below fair market value.
- Liquidity Position: Cash balance increased from $740,215 (April 30, 1998) to $249,149 (Oct 31, 1998) despite a significant cash burn from operations, primarily due to $6.1 million in proceeds from the sale of common stock and $811,000 from convertible debentures.
- Stock Issuances: Significant non-cash transactions included issuing stock for services ($28,050) and settling rent liabilities ($26,250).
Outlook, Risks, and Management Commentary
- Development Stage: Products are in pre-clinical trials. Significant additional financing is required for Phase I, II, and III human testing and FDA approval.
- Capital Needs: Management is actively pursuing strategic alliances and joint ventures. Future private placements are necessary to continue operations.
- Risks:
- No assurance that FDA approval will be granted.
- No assurance that necessary funding will be obtained.
- Substantial doubt about the ability to continue as a going concern.
- Commitments: Employment agreements with future commitments of $302,000 through March 2001.
- Market Risk: No exposure to foreign currency or interest rate risk; no derivative instruments.
Investor Verification Checklist
- Capital Runway: Verify if the $249,149 cash balance is sufficient to fund operations until the next financing round, given the $231,977 working capital deficit.
- Dilution Risk: Assess the impact of recent equity issuances (125,000 shares for rent, 170,000 shares for services, plus $6.1M stock sale) on existing shareholder value.
- Debt Obligations: Review terms of the $82,510 current portion of notes payable and $50,000 long-term notes payable.
- Regulatory Milestones: Confirm the specific timeline and costs associated with the upcoming pre-clinical and clinical trial phases.
- Going Concern Status: Evaluate the likelihood of securing the "significant additional financing" required to avoid insolvency.